Michael J. Wick, PhD, Chief Scientific Officer
Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline
Discover how XenoSTART’s clinic-to-bench pipeline delivers more clinically relevant PDX models, real-world patient data, and accelerated drug development. Patient-derived xenograft (PDX) models provide the most accurate way to mimic clinical tumor characteristics and behavior in preclinical studies. By directly transplanting tumor tissue from patients into immunodeficient hosts, resulting PDX models preserve the original human tumors’
Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline Read More »
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models One of the most significant areas of advancement in oncology is the growing capacity to match patients with therapies tailored to their unique cancer. As more relevant biomarkers and druggable targets are identified, drug developers still face an evergreen challenge: narrowing down the most
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models Read More »
